Treatment of anemia associated with chronic kidney disease with the HIF prolyl hydroxylase inhibitor enarodustat: A review of the evidence

Enarodustat, a newly developed hypoxia‐inducible factor prolyl hydroxylase inhibitor, is used in clinical practice in Japan. Several clinical studies showed that enarodustat corrected and maintained hemoglobin (Hb) levels by stimulating endogenous erythropoietin production and improving iron utiliza...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujikawa, Ryo, Nagao, Yuji, Fujioka, Masaki, Akizawa, Tadao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9539985/
https://www.ncbi.nlm.nih.gov/pubmed/35218616
http://dx.doi.org/10.1111/1744-9987.13820

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9539985/
https://www.ncbi.nlm.nih.gov/pubmed/35218616
http://dx.doi.org/10.1111/1744-9987.13820

Ejemplares similares